Role of Positron Emission Tomography/computed Tomography in the Evaluation of Renal Cell Carcinoma

Overview

Journal Indian J Urol

Specialty Urology

Date 2021 Jun 9

PMID 34103794

Citations 6

Authors

Rahul Jena

Tushar Aditya Narain

Uday Pratap Singh

Aneesh Srivastava

Affiliations

Soon will be listed here.

Abstract

Introduction: Positron emission tomography (PET) is not a standard recommendation in most of the major guidelines for the evaluation of renal cell carcinoma (RCC). Earlier studies evaluating PET scan in patients with RCC have provided discordant results. However, with the advent of newer hybrid PET/computed tomography (CT) scanning systems, this modality has shown increased efficacy in the evaluation of primary renal masses along with the detection of extrarenal metastases, restaging recurrent RCC, and also in monitoring response to targeted therapy. We performed a systematic review of the existing literature on the role of PET scan in the evaluation of RCC.

Methodology: We systematically searched the databases of PubMed/Medline, Embase, and Google Scholar to identify studies on the use of PET scan in RCC. Using Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines, 94 full-text articles were selected, of which 54 relevant articles were then reviewed, after a consensus by the authors.

Results: Several studies have shown similar sensitivity and specificity of fluoro-2-deoxy-2-d-glucose-PET (FDG-PET) scan as compared to conventional CT scan for the initial diagnosis of RCC, and an improved sensitivity and specificity for the detection of metastases and recurrences following curative therapy. The PET scan may also play a role in predicting the initial tumor biology and pathology and predicting the prognosis as well as the response to therapy.

Conclusion: The current guidelines do not recommend PET scan in the staging armamentarium of RCCs. However, FDG-PET scan is as efficacious, if not better than conventional imaging alone, in the evaluation of the primary and metastatic RCC, as well as in evaluating the response to therapy, due to its ability to pick up areas of increased metabolic activity early on. Newer tracers such as 68 prostate specific membrane antigen-labeled ligands may help in opening up newer avenues of theragnostics.

Citing Articles

The emerging role of oral microbiota in oral cancer initiation, progression and stemness.

Saikia P, Pathak L, Mitra S, Das B Front Immunol. 2023; 14:1198269.

PMID: 37954619 PMC: 10639169. DOI: 10.3389/fimmu.2023.1198269.

18F-fluoro-2-deoxy-2-d-glucose PET-CT (FDG PET-CT) in staging of high-risk renal and urothelial bladder cancers (COPPER-T) trial protocol.

Jena R, Bhargava P, Tripathi S, Taywade S, Yadav T, Sandhu A BJUI Compass. 2023; 4(6):662-667.

PMID: 37818027 PMC: 10560619. DOI: 10.1002/bco2.246.

SEOM SOGUG clinical guideline for treatment of kidney cancer (2022).

Mendez-Vidal M, Lazaro Quintela M, Lainez-Milagro N, Perez-Valderrama B, Suarez Rodriguez C, Arranz Arija J Clin Transl Oncol. 2023; 25(9):2732-2748.

PMID: 37556095 PMC: 10425490. DOI: 10.1007/s12094-023-03276-5.

Prognostic Significance of F-FDG PET/CT Imaging in Survival Outcomes in Patients with Renal Cell Carcinoma.

Tatar G, Gundogan C, Sahin O, Arslan E, Ergul N, Cermik T Mol Imaging Radionucl Ther. 2022; 31(3):200-206.

PMID: 36268871 PMC: 9585999. DOI: 10.4274/mirt.galenos.2022.42744.

Recent advances in imaging techniques of renal masses.

Aggarwal A, Das C, Sharma S World J Radiol. 2022; 14(6):137-150.

PMID: 35978979 PMC: 9258310. DOI: 10.4329/wjr.v14.i6.137.

References

van Es S, Brouwers A, Mahesh S, Leliveld-Kors A, de Jong I, Lub-de Hooge M . Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma. J Nucl Med. 2017; 58(6):905-910. DOI: 10.2967/jnumed.116.183475. View

Liu Y, Ghesani N, Zuckier L . Physiology and pathophysiology of incidental findings detected on FDG-PET scintigraphy. Semin Nucl Med. 2010; 40(4):294-315. DOI: 10.1053/j.semnuclmed.2010.02.002. View

Namura K, Minamimoto R, Yao M, Makiyama K, Murakami T, Sano F . Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer. 2010; 10:667. PMC: 3016292. DOI: 10.1186/1471-2407-10-667. View

Antunes J, Viswanath S, Rusu M, Valls L, Hoimes C, Avril N . Radiomics Analysis on FLT-PET/MRI for Characterization of Early Treatment Response in Renal Cell Carcinoma: A Proof-of-Concept Study. Transl Oncol. 2016; 9(2):155-162. PMC: 4833889. DOI: 10.1016/j.tranon.2016.01.008. View

Lencioni R, Llovet J . Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30(1):52-60. DOI: 10.1055/s-0030-1247132. View

Bertagna F, Motta F, Bertoli M, Bosio G, Fisogni S, Tardanico R . Role of F18-FDG-PET/CT in restaging patients affected by renal carcinoma. Nucl Med Rev Cent East Eur. 2013; 16(1):3-8. DOI: 10.5603/NMR.2013.0002. View

Alongi P, Picchio M, Zattoni F, Spallino M, Gianolli L, Saladini G . Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. Eur J Nucl Med Mol Imaging. 2015; 43(3):464-73. DOI: 10.1007/s00259-015-3159-6. View

Wahl R, Harney J, Hutchins G, Grossman H . Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: pilot animal and human studies. J Urol. 1991; 146(6):1470-4. DOI: 10.1016/s0022-5347(17)38141-7. View

Knight S, Delbeke D, Stewart J, Sandler M . Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. Chest. 1996; 109(4):982-8. DOI: 10.1378/chest.109.4.982. View

10.

Gundogan C, Cermik T, Erkan E, Yardimci A, Behzatoglu K, Tatar G . Role of contrast-enhanced 18F-FDG PET/CT imaging in the diagnosis and staging of renal tumors. Nucl Med Commun. 2018; 39(12):1174-1182. DOI: 10.1097/MNM.0000000000000915. View

11.

Kakizoe M, Yao M, Tateishi U, Minamimoto R, Ueno D, Namura K . The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ. BMC Cancer. 2014; 14:390. PMC: 4067124. DOI: 10.1186/1471-2407-14-390. View

12.

Vogel C, Ziegelmuller B, Ljungberg B, Bensalah K, Bex A, Canfield S . Imaging in Suspected Renal-Cell Carcinoma: Systematic Review. Clin Genitourin Cancer. 2018; 17(2):e345-e355. DOI: 10.1016/j.clgc.2018.07.024. View

13.

Sacco E, Pinto F, Totaro A, DAddessi A, Racioppi M, Gulino G . Imaging of renal cell carcinoma: state of the art and recent advances. Urol Int. 2010; 86(2):125-39. DOI: 10.1159/000322724. View

14.

Miyakita H, Tokunaga M, Onda H, Usui Y, Kinoshita H, Kawamura N . Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol. 2002; 9(1):15-8. DOI: 10.1046/j.1442-2042.2002.00416.x. View

15.

Das C, Thingujam U, Panda A, Sharma S, Gupta A . Perfusion computed tomography in renal cell carcinoma. World J Radiol. 2015; 7(7):170-9. PMC: 4506935. DOI: 10.4329/wjr.v7.i7.170. View

16.

Gerety E, Lawrence E, Wason J, Yan H, Hilborne S, Buscombe J . Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design. Ann Oncol. 2015; 26(10):2113-8. PMC: 4576907. DOI: 10.1093/annonc/mdv289. View

17.

Wu H, Yen R, Shen Y, Kao C, Lin C, Lee C . Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas - a preliminary report. J Cancer Res Clin Oncol. 2002; 128(9):503-6. DOI: 10.1007/s00432-002-0370-1. View

18.

Fuccio C, Ceci F, Castellucci P, Spinapolice E, Palumbo R, DAmbrosio D . Restaging clear cell renal carcinoma with 18F-FDG PET/CT. Clin Nucl Med. 2014; 39(6):e320-4. DOI: 10.1097/RLU.0000000000000382. View

19.

Ozulker T, Ozulker F, Ozbek E, Ozpacaci T . A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses. Nucl Med Commun. 2011; 32(4):265-72. DOI: 10.1097/MNM.0b013e3283442e3b. View

20.

Goldberg M, Mayo-Smith W, PAPANICOLAOU N, Fischman A, Lee M . FDG PET characterization of renal masses: preliminary experience. Clin Radiol. 1997; 52(7):510-5. DOI: 10.1016/s0009-9260(97)80327-3. View